Home ›
Entities
› academia
› Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
Research article (Therapeutic Advances in Medical Oncology, 2020) · cited 14× · AI/ML
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
Summary
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer is a scholarly article[1].
Key Facts
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. Retrieved May 24, 2026, from https://4ort.xyz/entity/clinical-and-molecular-factors-for-selection-of-nivolumab-or-irinotecan-as-third-line-treatment-for-advanced-gastric-can
MLA“Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/clinical-and-molecular-factors-for-selection-of-nivolumab-or-irinotecan-as-third-line-treatment-for-advanced-gastric-can.
BibTeX@misc{4ortxyz_clinical-and-molecular-factors-for-selection-of-nivolumab-or-irinotecan-as-third-line-treatment-for-advanced-gastric-can_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer}}, year = {2026}, url = {https://4ort.xyz/entity/clinical-and-molecular-factors-for-selection-of-nivolumab-or-irinotecan-as-third-line-treatment-for-advanced-gastric-can}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer — https://4ort.xyz/entity/clinical-and-molecular-factors-for-selection-of-nivolumab-or-irinotecan-as-third-line-treatment-for-advanced-gastric-can (retrieved 2026-05-24)
